ERBB2 and breast cancer: The pre-existing anti-tumor immunity, as indicated by baseline TIL count and CD8 + TIL count, is strongly associated with better response to neoadjuvant chemotherapy (NAC) and better prognosis, especially in TNBCs and HER2 positive breast cancers [9,109].